Switzerland-based Debiopharm Group has initiated patient treatment in a Phase I clinical trial of Debio 1347, an orally available small molecule targeting advanced solid tumours with FGFR alterations.

The Phase I trial is an open label multicentre study of Debio 1347 (CH5183284), a selective FGFR 1, 2, 3 inhibitor, in patients with advanced solid tumours.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The study is aimed at identifying the dose limiting toxicity (DLT), as well as assessing the maximal tolerated dose (MTD) of Debio 1347 based on the safety and tolerability of the product during a daily oral administration to patients suffering from advanced solid malignancies that have an alteration of the FGFR 1, 2 or 3 genes.

"Debio 1347 is going to be developed with a companion diagnostic and we believe it could become a personalised treatment option for patients suffering from solid tumours which could significantly improve their outcomes."

Under the expansion part, the study will also evaluate the safety profile at the recommended dose of Debio 1347 in a larger group of patients.

Debiopharm Group president and founder Rolland-Yves Mauvernay said: "Debio 1347 (CH5183284) is going to be developed with a companion diagnostic and we believe it could become a personalised treatment option for patients suffering from solid tumours which could significantly improve their outcomes."

A licence agreement has been signed between Debiopharm and Chugai Pharmaceutical in December 2012 for the development and commercialisation of Debio 1347 in all countries.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Debio 1347 is currently being tested in a Phase I in several oncology centres of excellence in the US and Europe.

It is expected to become a tailored treatment with high anti-tumour activity.